Stelios Astaras

Mr. Stelios Astaras

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 May 2026 in Biomolecules
Verified
Journal Article
Open access
PDF file
APAdamantia Papadopoulou
Adamantia Papadopoulou
SASocratis Avgeris
Socratis Avgeris
STSavvas Thysiadis
Savvas Thysiadis
CSChristos Siokatas
Christos Siokatas
SAStelios Astaras
Stelios Astaras
Dimitris KletsasDimitris Kletsas
Dimitris Kletsas
Ninety-five structurally diverse chemically synthesized compounds, retrieved from the chemical library of the national research infrastructure OPENSCREEN-GR, were subjected here to a structure-agnostic bioactivity-driven screen focused on putative anti-cancer activities using a number of human cell lines derived from diverse types of cancer. Interestingly, the top four compounds that displayed a broad anti-cancer activity (with no apparent photosensitizing activity) during unbiased biological evaluation were then identified as phenoxazine derivatives. In addition to their cytotoxic activity, phenoxazine derivatives BS115 and ST61 were also found to be cytostatic by inducing a p53-independent G2/M cell cycle arrest as well as a G0/G1 arrest only in cells harboring a functional p53. A kinetics analysis using two multiplex immunoassays and siRNA-mediated knockdown of HSP27 revealed that the latter protein is a key molecule in the response of cancer cells to ST61 via its phosphorylation by p38 MAPK. The main mechanism underlying ST61’s anti-cancer activity was found to involve oxidative stress, as scavenging of ST61-induced reactive oxygen species by N-acetyl-cysteine led to the abrogation of the compound’s cytotoxic effect.